The class of chemicals described as Vmn1r163 Inhibitors does not refer to a specific set of compounds directly targeting the Vmn1r163 receptor. Instead, this class broadly includes compounds that could indirectly affect the function of Vmn1r163 by acting on related signaling pathways or cellular processes.
These compounds exert their influence through various mechanisms within the GPCR signaling cascade, which is a common signaling mechanism for a wide range of cellular responses. The list includes both inhibitors and activators of enzymes like adenylate cyclase which alters the levels of cAMP, a common second messenger in GPCR signaling. Modulation of kinase activity is another point of intervention; kinases such as protein kinase A and protein kinase C play critical roles in the phosphorylation events that follow GPCR activation. By inhibiting these kinases, the phosphorylation and thus the signaling cascade that might include Vmn1r163 can be affected. Additionally, modulation of calcium signaling through compounds like U73122 and 2-APB affects the release of calcium from intracellular stores, which is a crucial step in many GPCR signaling pathways, including potentially those involving Vmn1r163. By altering the levels of intracellular calcium, these compounds can influence the activity of various calcium-dependent processes that may be downstream of Vmn1r163 signaling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Beta-adrenergic antagonist that can inhibit G-protein signaling, potentially reducing Vmn1r163 activity. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Blocks beta-adrenergic receptors, possibly affecting G-protein-coupled processes including those related to Vmn1r163. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Alpha2-adrenergic antagonist that can alter norepinephrine signaling, indirectly modulating Vmn1r163-related pathways. | ||||||
SQ 22536 | 17318-31-9 | sc-201572 sc-201572A | 5 mg 25 mg | $95.00 $363.00 | 13 | |
Adenylate cyclase inhibitor, potentially reducing cAMP levels and affecting Vmn1r163 signaling indirectly. | ||||||
KT 5720 | 108068-98-0 | sc-3538 sc-3538A sc-3538B | 50 µg 100 µg 500 µg | $138.00 $220.00 $972.00 | 47 | |
Inhibits protein kinase A which is downstream of cAMP, potentially affecting signaling cascades involving Vmn1r163. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Protein kinase C inhibitor that could disrupt downstream signaling pathways of Vmn1r163. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $28.00 $53.00 | 37 | |
Modulator of IP3 receptors that can affect calcium signaling, potentially influencing Vmn1r163 signaling cascades. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Inhibits protein kinase C, potentially affecting downstream effects of Vmn1r163 activation. | ||||||